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Identification of nosocomial infection rates 
that are out of control 
W. Scheckler. University of Wisconsin, St. Mary’s Hospital, Madison, 
wr, USA 
Objectives: To review elements necessary for the development of 
reliable nosocomial infection rates and comparison strategies 
appropriate to verify the need to reduce those rates. 
Methods: The National Nosocomial Infection Surveillance 
system (NNIS) of the USAS Center for Disease Control and 
Prevention has become the current de facto US standard for 
definitions used in surveillance of nosocomial infections: both 
numerator-specific infections, and denominators for populations at 
risk for infections. The NNIS system is also a paradigm for hospitals 
to compare specific rates and assess statistically significant differences 
in those rates. Practical issues will be illustrated with cases from the 
author‘s hospital discussing interventions done when rates were out 
of control, issues of thoroughness and comparability of surveillance 
completeness, and pitfalls of inter-hospital comparisons versus intra- 
hospital tracking of rates. Focused surveillance of specific nosocomial 
infections is now recommended, and ‘hospital-wide’ rates are not 
interpretable. Parameter guidelines have been developed for evalu- 
ating outcome indicators with a focus on nosocomial infection 
incidence rates. These guidelines should be used when deciding on 
the selection of rates for monitoring and comparison. 
Results: Twenty-eight years of experience with the NNIS system 
has provided a substantial amount of data for helping to define out- 
of-control nosocomial infection rates. 
Conclusions: Careful application of NNIS methodology, 
selection of incidence rates of nosocomial infection most important 
to the hospital population of interest, and familiarity with issues 
essential in attempts at comparison of one’s own rates with others, 
can lead to better patient care and appropriate public accountability 
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New developments in pediatric pneumococcal 
infections 
R. Dagan. Pediatric Infectious Disease Unit, Soroka University Medical 
Center and the Faculty of Health Sciences, Ben-Gurion University of the 
Negey Beer-Sheva, Israel 
Antibiotic-resistant pneumococci (R-Pnc) are emerging as a cause of 
great burden on pediatric patients and pediatricians. While pneu- 
monia may be most often still treated with the regular regimens, the 
treatment of meningitis calls for a complex and expensive approach 
and the treatment of acute otitis media (AOM) ends often in 
bacteriologic and clinical failures. Although for pediatric meningitis 
several new drugs such as the respiratory quinolones may be helpful, 
it is unlikely that in the next few years the new antibiotics will solve 
most of the problems, especially in AOM. Of the new approaches, 
the two most attractive ones are: (1) withholding antibiotics in cases 
where antibiotic treatment is not absolutely needed, which may 
reduce their use by 50%; and (2) Pnc immunization. Policies and 
guidelines for the reduction idwitholding of antibiotic use in the 
community are urgently needed. Various conjugate Pnc vaccines 
have been shown so far to be safe and immunogenic in infants and 
children. Furthermore, preliminary data show their efficacy in 
reducing Pnc invasive infections and carriage of both Pnc in general 
and R-Pnc in particular. The next 5 years will be of great interest, 
since the success in implementing the new approaches, i.e. the 
reduction of antibiotic use and the role of the new Pnc vaccine, will 
be assessed in detail. 
Viral central nervous system (CNS) infections 
at the end of the 20th century 
L. Szenborn. Clinicfor Pediatric Infectious Diseases, Wroclaw, Poland 
Viral infections of the CNS occur most commonly in childhood. 
Most of them either involve the meninges, as aseptic meningitis 
(AM), or cause a mild clinical syndrome of meningoencephalitis 
rather than the alarming forms of encephalitis. Diagnosis is usually 
based on the combination of clinical assessment, exlusion of other 
causes and specific investigations. They include: EEG, CT, MRI, and 
cerebrospinal fluid (CSF) microscopy and culture. The use of 
polymerase chain reaction (PCR) has improved understanding of the 
etiology and pathogenesis of viral infections of the CNS. Most AM 
cases are associated with non-polio enteroviral (npEV) and mumps 
virus infections. Severe persistent npEV infections have been 
observed in immunocompromised patients, and patients with 
agammaglobulinemia. In mumps, more significant neurologic 
involvement can occur but full recovery is the rule. Herpes simplex 
encephalitis (HE) is the most common sporadic fatal encephalitis in 
the Western world. The clinical presentation of HE ranges from a 
mild illness to diffuse cerebral disease and focal necrotizing lesions. 
Rubella and CMV can cause catastrophic brain infections in the fetus 
and HSV2 in the neonate. VZV can cause a cerebellitis or involve 
cortical gray matter. The outcome of HE is directly related to the 
rapidity of the diagnosis, and immediate implementation of a specific 
antiviral therapy Other viral pathogens in Europe (measles, HHV6, 
HHV7, HIV, EBV and arboviruses) can also cause encephalitis. In 
summary, a high index of suspicion and a rapid diagnostic and 
therapeutic approach may influence the outcome of the ‘treatable’ 
causes of encephalitis. Unfortunately, in the majority of cases, no 
specific treatment is available and supportive therapy is the corner- 
stone of treatment. 
lick-associated infections 
D. Nadal. Ittjectious Diseases, University Children’s Hospital of Zurich, 
Zurich, Switzerland 
Ticks can efficiently transmit a variety of viruses, bacteria, and 
protozoa. This presentation will focus on the most commonly 
diagnosed tick-borne infections in Europe, including arboviruses, 
Borrelia burgdoferi, and the most recently recognized agent of human 
granulocytic ehrlichiosis (HGE). Transmission of these pathogens 
occurs in spring and summer, the seasons of activity of the vectors. 
Most arboviral infections go unrecognized, since they manifest as flu- 
like illnesses. About 10% of infections proceed to involve the central 
nervous system and present with signs and symptoms of meningitis 
or meningoencephalitis. Severe forms are rare in children, who also 
exhibit less neurologic sequelae than adults. Serology is accurate and 
the method of choice to establish etiologic diagnosis. The clinical 
manifestations of B. burgdoferi infection may include cutaneous, 
arthritic, myocardial or neurologic disorders. They appear to be 
somewhat dictated by the nature of the involved B. burgdoferi strain. 
Whereas etiologic diagnosis of skin alterations may rely on clinical 
grounds, diagnosis of other manifestations requires backup by sero- 
logy or detection of B. bugdoferi. Both approaches are burdened with 
obstacles. Human granulocytic ehrlichiosis may present as flu-like 
illness, different rashes, leuko- and thrombocytopenia, and elevation 
of serum transaminase levels. Detection of the agent of HGE in blood 
smears ascertains the diagnosis but has a low sensitivity. Serologic 
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diagnoais is still probiematic. Effective causal treatment is available 
only for infections with B. bugdoferi and HGE. By contrast, primary 
prevention by imniunization is at hand against arboviruses only. The 
efficacy of vaccines against B. burgdotjki recently studied in the USA 
has yet to be determined in Europe. 
Hemolytic uremic syndrome 
D. Karpinan'.',.', J.U. Kaper ', C. Svanborg". Departnicrits of 
'Laboratory Medicine and ' Pediatria, University ~$Lirrmd, Lund, 
Sweden; .'Center.for bhccirre r)aveloyment, Unirmsity qf Maryland, 
Baltimore, MD, USA 
Postenteropathic hemolytic uremic syndrome (HUS) is preceded by 
diarrhca or hemorrhagic colitis and is characterized by inicro- 
angiopathic hemolytic anemia, throinbocytopenia and acute renal 
failure. It has been associated with entcrohemorrhagic Esrliericliia coli 
(EHEC) isolated from patients during large food- and water-borne 
outbreaks. The bacteria produce several well-characterized virulence 
factors such as: Shiga toxin (Stx) which is cytotoxic to human renal 
endothelial and epithelial cells and rabbit intestinal epithelial cells; 
intimin, an outer-membrane protein, which mediates intimate 
intestinal colonization, and its receptor, E. coli secretory protein EspE, 
which is transferred from the bacteria to the eukaryotic cell; Esps A, 
I3 and 11, which activate the signal transduction events necessary for 
the formation of intestinal attachment and effacement lesions; and 
lipopolysaccharide. Both lipopolysaccharide and Stx-2 are important 
for disease developiiieiit in a mouse inodel of EHEC infection. Mice 
develop gasti-ointestinai, neurologic and systemic symptoms, 
gloniernlar and tubular apoptosis, necrotic and apoptotic foci in the 
colon and fragmented erythrocytes. These aspects of disease resemble 
human HUS. Even mice inoculated with EHEC strains that do not 
produce intimin or Esp A and B develop similar symptoms and 
pathology. Children with HUS mount an antibody response to 
intimin, Esp A and Esp B which may be useful for detection of 
EHEC infection. Infected chiidren also secrete large amounts of  
interleukin-6 in their urine. Stimulation of pediatric renal tubular 
cells with Stx leads to the secretion of large amounts of interleukin- 
6, which may play a role in the host response to EHEC infection. 
New developments in treatment of 
respiratory tract infections 
Antimicrobial spectrum of moxifloxacin 
A. Dalhoff. R o p r  AG, Plrarnza Research Center, Wnppertal, Gcrrriany 
Moxifloxacin is a new 8-methoxyquinolonc that is highly effective 
against all predominant respiratory pathogens, including: Gram- 
positive (i.e. Strcytococitrs pnrurnoniaej, Gram-negative (i.e. Haemo- 
pliiltrs iriiitenznc and ,bforaxellu catarrhah) and atypical (i.e. Clilanzydia 
pwetrvnoniac and Lc@oncl/a pneirmophi/a) bacteria. In contrast to 
fluoroquinolone agents, which showed greater Gram-negative than 
Gram-positive activity, moxifloxacin has been shown to be highly 
active against S .  pncuinoniae, including penicillin-resistant strains 
(MICWIF 0.06-0.12 nig/L) while retaining excellent Gram-negative 
activity (MlCsus for H. itzflueirzae and M .  catarrhah (including beta- 
lactamase-producing strains) <0.12 mg/L). Several studies of dis- 
sociated fluoroquinolone resistance have shown that moxifloxacin 
may have a lower potential than other quinolones to induce bacterial 
resistance. This phenomenon may be attributable to rnoxifloxacin's 
high intrinsic activity for two intracellular targets: DNA topo- 
isomerase IV (Grain-positivr organicins) a n d  DNA gr , ise  (Graiii- 
negative organisms). Addition of a methoxy group to Nl-cyclo- 
propyl flnoroquinolones improves lethal activity Conseqiiently, C% 
rnethoxy derivatives, such as moxifloxacin, restrict the acquisition of 
resistance by bacterial populations; moxifloxacin retains high activity 
against first- and second-step ciprofloxacin- aiid ofloxac in-resistant 
mutants. Hence, the employment of ii~oxifloxaciii for the manage- 
ment of respiratory tract infections may be ecologicnlly prcfcrable, 
since its high in vitro potency and reduced propensity to elicit 
bacterial resistance may curtail the spread of resistant strain\. This 
presentation will review the in vitro profile of inoxifloxxin vcr\us 
other fluoroquiiiolones and conventional firrt-line agent5 for thc 
management of conimunity-acquired respiratory tract infection\. 
p] Pharmacokinetics and pharmacodynamics 
J. Schentag. Clinical Pliarmamkinetirs Lahorator)), lVf~z%llard Fi//rnor? 
Hospital, Bi@alo, Ncio Mwk, (JSA 
Pharmacokinetic aiid pharmacodyiiamic data for antibdctcrial agents 
can be integrated into several ratios, including: (1) the wed under the 
conceiitration-tiiiie curve (AUC) to the ininiinum inhibitory c011- 
centration of the pathogen (AUCIMIC) or AUIC (which is thc 
AUC/MIC normalized for 24 h), and (2) the peak \eruiii 
) to the MIC (C,,,.,,/MIC). With other quino- 
lones, AUIC values above 125 and C,,,,,/MIC ratios of 8-10 have 
been associated with optimal antibacterial activity. Lower values nny 
relate to less rapid bactericidal activity and the selection of resistant 
bacteria. This target AUIC may be achieved with a singlc antibiotic 
or it can be the sum ofAUIC values oftwo or iiiore antibiotics. There 
is considerable variability in the actual AUIC value for patients when 
antibiotics are given in their usually recommended dotages. The 
achievement of minimally effective antibiotic action, contisting of an 
AUIC above 125, is associated with bacterial eradication in about 7 
days for beta-lactams and quinolones. When AUIC is increased 
to 250, the quinolone ciprofloxacin (which disyhys i n  vivo 
concentration-dependent bacterial killing) can eliininatc thr bxterial 
pathogen in 1-2 days. Beta-lactams, even when d o d  to an AUIC 
of 250, often require longer treatment duration to eliminate the 
bacterial pathogen, because the in vivo bacterial killing rate is slower 
with beta-laccams than with the quinolones. This remain\ true evcn 
at AUIC values of 250 for both conipounds, which i\ theoretically 
identical dosing. The  new 8-mcthoxyqiiinolone agrnt nioxifloxxin 
has been shown to reach AUIC and C,,,.a,/MI(:wj values considerably 
greater than the ideal values of 125 and 12, respectively, thdt are 
necessary to effect rapid eradication of potential pathogens. The C,,,.,, 
long half-life (10-12 h) and inherent in vitro antibacterial activity 
against a broad range of pathogenic bacteria suggest that n~oxifloxacin 
will be useful for the treatment of a variety of respiratory tract and 
other infections. 
Js187) Bronchitis overview 
R. Wilson. Royal Bronipfon Hospird arid hiperid C d q r  of Srierrw, 
Echndupy and i\/lediririe, at hktiotial Hmrr arid L i q  Imritrtrc, L ~ J ~ I ~ o ~ I ,  
UK 
Acute exacerbations of chronic obstryctive pulmonary disease 
(COPD) are common, as a reason for both general practice c o n u -  
tation7 and hospital admissions. They have a major impact on  
patients' quality of life, which may take up to 6 weeks to return to 
baseline. Bacterial infection of the respiratory inucosa occurs in at 
least half of the cases. This attracts dn inflaminatory responre which 
may clear the infection. Spontaneous resolution is less likely to occur 
